Javier Urzay, deputy director of Farmaindustria: “We want to turn Spain into one of the most attractive places in the world to do biomedical research”
Source: Farmaindustria.es
“In this country we have a first-line healthcare system, well-trained health professionals, excellent research centers, committed patient organizations and pioneering legislation in Europe. Along with the commitment of pharmaceutical companies, the goal of all is to make Spain one of the most attractive places in the world to do biomedical research. ” This is how Javier Urzay, deputy general director of Farmaindustria, condenses the challenge faced by all the Spanish biosanitary tissue at present and that will be analyzed and discussed at the 12th Annual Conference of the Biomedical Research Technology Platforms, which is being held the next 5 and March 6 in Madrid.
The road to achieve that goal is already partially traveled. Spain accumulates a considerable experience in public-private collaboration in preclinical research, and advances with firm step in the clinic, to the point that already a third of all the tests carried out in Europe already have Spanish participation. “And for some multinational pharmaceutical company, our country is already one of its two or three first elections to develop its research activity,” explains Urzay. In the same sense, the experience with the new gene and cellular therapies, where health professionals, hospitals and companies participate and even lead international initiatives of significance.
Attraction pole
On this solid foundation, the final objective, in which Farmaindustria works decisively, is to turn Spain into one of the main poles of attraction of international biomedical innovation projects.
For Urzay, the XII edition of the Conference will be a good example of the collaborative spirit with which all agents of the biomedical sector work to achieve and consolidate such an ambitious goal. “Public Administration, health professionals, researchers, patients and laboratories; We all go hand in hand in this process. From the early adaptation of European regulations to Spanish legislation to the use of Big Data in drug R & D, including the growing participation of patient associations in research activities; everything adds up “, explains the person in charge of the employer’s association.
Clear bet
In this sense, Urzay highlights the importance of the Health Administration accompanying with a clear commitment to access innovation, so that Spain does not lose ground in front of the major countries of reference, and within a policy, with which the The pharmaceutical industry is also committed to evaluating health outcomes and reconciling them with sustainability.
“Biomedical research is already responding to a new model,” concludes the Farmaindustria representative. It is collaborative, international and multicentric. There is a big competition between different countries of the world. And we have much in our favor to be well positioned. Spain can not miss this train. ”
In Distefar we echo this news in which Urzay highlights the importance of the Health Administration accompanying with a clear commitment to access innovation, so that Spain does not lose ground in front of the major countries of reference.
